ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Organogenesis Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.02+0.02 (+2.03%)
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Organogenesis statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Organogenesis | Industry median |
|---|---|---|
| Market Cap | $131.25M | $164.85M |
| Enterprise Value | $85.15M | $87.06M |
| PS Ratio | 0.29 | 3.60 |
| PB Ratio | 0.89 | 2.03 |
| P/TBV Ratio | 1.13 | 2.31 |
| P/FCF Ratio | 6.30 | 17.44 |
| P/OCF Ratio | 4.10 | 13.32 |
Enterprise value
| Measure | Organogenesis | Industry median |
|---|---|---|
| EV / Sales | 0.19 | 2.43 |
| EV / FCF | 4.09 | 20.97 |
Income (trailing twelve months)
| Measure | Organogenesis | Industry median |
|---|---|---|
| Revenue | $457.45M | $57.94M |
| Operating Income | -$35.87M | -$21.44M |
| Pretax Income | -$34.77M | -$14.45M |
| Net Income | -$84.16M | -$22.46M |
| EBITDA | -$19.93M | -$16.91M |
| EPS (Diluted) | -$0.85 | -$0.83 |
Margins
| Measure | Organogenesis | Industry median |
|---|---|---|
| Operating Margin | -7.84% | -44.5% |
| Pretax Margin | -7.60% | -13.0% |
| Profit Margin | -18.4% | -39.2% |
| EBITDA Margin | -4.36% | -31.3% |
| FCF Margin | 4.56% | -8.85% |
Returns
| Measure | Organogenesis | Industry median |
|---|---|---|
| Return on Equity (ROE) | -44.1% | -53.1% |
| Return on Assets (ROA) | -19.4% | -41.0% |
| Return on Invested Capital (ROIC) | -21.7% | -32.0% |
| Return on Capital Employed (ROCE) | -10.3% | -37.8% |
Growth
| Measure | Organogenesis | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 6.50% | 6.01% |
| Revenue Growth (3Y CAGR) | 7.76% | 2.25% |
| Revenue Growth (5Y CAGR) | 10.8% | 6.42% |
| EPS Growth (3Y CAGR) | 7.72% | -0.17% |
| EPS Growth (5Y CAGR) | 0.00% | 3.77% |
Balance sheet
| Measure | Organogenesis | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $46.10M | $62.42M |
| Net Cash (Debt) | $46.10M | $15.68M |
| Net Cash Per Share | $0.36 | $0.66 |
| Equity (Book Value) | $148.27M | $48.79M |
| Book Value Per Share | $1.15 | $1.36 |
| Tangible Book Value | $116.49M | $23.06M |
| Working Capital | $143.34M | $75.77M |
Financial position
| Measure | Organogenesis | Industry median |
|---|---|---|
| Current Ratio | 3.52 | 3.30 |
| Quick Ratio | 2.58 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Organogenesis | Industry median |
|---|---|---|
| Operating Cash Flow | $31.97M | -$12.35M |
| Capital Expenditures | -$11.13M | -$1.06M |
| Free Cash Flow | $20.84M | -$20.28M |
| FCF Per Share | $0.16 | -$0.42 |
Efficiency
| Measure | Organogenesis | Industry median |
|---|---|---|
| Asset Turnover | 1.05 | 0.38 |
| Revenue Per Employee | $535.66K | $398.96K |
| Profits Per Employee | -$98.54K | -$703.34K |
| Employee Count | 854 | 74 |
Dividends and yields
| Measure | Organogenesis | Industry median |
|---|---|---|
| Earnings Yield | -64.1% | -22.7% |
| FCF Yield | 15.9% | -9.07% |
Shares
| Measure | Organogenesis | Industry median |
|---|---|---|
| Shares Outstanding | 128,675,000 | 58,179,650 |
| Shares Change (YoY) | 2.23% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Shares Held by Institutions | 53.2% | 59.4% |
Taxes
| Measure | Organogenesis | Industry median |
|---|---|---|
| Income Tax | $49.39M | $91.50K |
Scores
| Measure | Organogenesis | Industry median |
|---|---|---|
| Altman Z-Score | 1.40 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Organogenesis's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.